PANews reported on June 3 that NewLimit, an anti-aging company co-founded by Coinbase founder and CEO Brian Armstrong, has completed a $435 million Series C funding round. The round was led by Founders Fund, with participation from new investors Thrive Capital, Greenoaks, and Quiet Capital, as well as existing investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital.

Furthermore, according to the Wall Street Journal , NewLimit's valuation reached $3.1 billion in this funding round, more than double that of a year ago. The company focuses on reversing cellular aging but currently has no products on the market. Its first drug for alcohol-related liver disease will begin human trials next year.